Ian Mortimer is President and Chief Executive Officer of Xenon Pharmaceuticals Inc. (XENE). The company reported total compensation of $9,221,712 for fiscal year 2025.
| Salary | $786,000 |
|---|---|
| Bonus | $0 |
| Stock awards | $1,774,000 |
| Option awards | $6,065,255 |
| Non-equity incentive plan | $550,200 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $46,257 |
| Total | $9,221,712 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Xenon Pharmaceuticals Inc. filed April 22, 2026, accession 0001193125-26-170320.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Ian Mortimer this page | President and Chief Executive Officer | $9,221,712 |
| Thomas Kelly | Chief Financial Officer | $7,238,664 |
| Darren Cline | Chief Commercial Officer | $4,048,214 |
| Christopher Kenney | Chief Medical Officer | $3,145,290 |
| Andrea DiFabio | Chief Legal Officer and Corporate Secretary | $3,062,790 |
| Sherry Aulin | Former Chief Financial Officer | $356,453 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Xenon Pharmaceuticals Inc. compensation brief.
Ian Mortimer's compensation sits inside Xenon Pharmaceuticals Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.